| Ying, Jieer |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT06383533: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Disitamab Vedotin Plus Cadonilimab | Zhejiang Cancer Hospital | Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation | 05/25 | 12/25 | | |
NCT06393166: Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 37 | RoW | Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection | Zhejiang Cancer Hospital | Non-Resectable Pancreas Carcinoma | 05/25 | 12/25 | | |
NCT06046963: Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites |
|
|
| Recruiting | 2 | 35 | RoW | Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected | Zhejiang Cancer Hospital | Gastric Cancer, Peritoneal Metastases, Ascites, Malignant | 03/24 | 03/25 | | |
NCT05559775: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy |
|
|
| Recruiting | 2 | 20 | RoW | Pemigatinib Pill, Pemazyre | Zhejiang Cancer Hospital | Gastrointestinal Cancer | 08/24 | 08/25 | | |
NCT06092645: Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma |
|
|
| Recruiting | 2 | 48 | RoW | surufatinib plus cadonilimab, surufatinib plus AK104 | Zhejiang Cancer Hospital | Bile Duct Adenocarcinoma | 10/24 | 10/25 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT05864105: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 35 | RoW | PM8002, FOLFOX regimen | Biotheus Inc. | Hepatocellular Carcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 51 | RoW | AST-3424 | Ascentawits Pharmaceuticals, Ltd | Advanced Solid Tumors, Hepatocellular Carcinoma | 11/25 | 11/25 | | |
| Recruiting | 1/2 | 250 | RoW | AK112, AK117, Chemotherapy | Akeso | Advanced Malignant Tumors | 08/24 | 01/25 | | |
| Recruiting | 1/2 | 90 | RoW | cadonilimab, AK104, Trastuzumab, XELOX, Disitamab Vedotin, RC48, mFOLFOX6 | Zhejiang Cancer Hospital | Metastatic HER2 Positive Gastroesophageal Junction Cancer | 08/26 | 12/27 | | |
NCT06572319: Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens |
|
|
| Recruiting | 1/2 | 35 | RoW | Disitamab Vedotin(RC48) Plus Tratuzumab | Zhejiang Cancer Hospital | HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 08/26 | 12/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma |
|
|
| Terminated | 1 | 21 | RoW | Mitoxantrone Hydrochloride Liposome, intravenous injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Gastric Carcinoma | 05/22 | 05/22 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT06048289: Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy |
|
|
| Recruiting | N/A | 150 | RoW | Blood samples, tumor biopsy specimens will be collected | Zhejiang Cancer Hospital | Biliary Tract Tumor, Cholangiocarcinoma | 03/24 | 03/25 | | |
